Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02339818 · ClinicalTrials.gov registry record
Evaluation of the Effectiveness of Eliquis ® (Apixaban) Risk Minimization Tools in European Economic Area (EEA) Countries
A clinical trial, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- 126
- Enrollment target
NCT02339818 is a clinical trial that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 126 participants.
The verdict
NCT02339818 has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- 126 participants
- Enrollment target
Study Summary
The main purpose is to evaluate the effectiveness of the Eliquis® (apixaban) Prescriber Guide and Patient Alert Card in terms knowledge of the important identified risk of bleeding associated with Eliquis treatment communicated by the RM tools.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 126 participants |
| Start Date | 2015-08 |
| Est. Completion | 2017-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02339818
The ClinicalTrials.gov registry entry for NCT02339818 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 126 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02339818 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02339818 about?
NCT02339818 is a clinical study titled "Evaluation of the Effectiveness of Eliquis ® (Apixaban) Risk Minimization Tools in European Economic Area (EEA) Countries". The main purpose is to evaluate the effectiveness of the Eliquis® (apixaban) Prescriber Guide and Patient Alert Card in terms knowledge of the important identified risk of bleeding associated with Eliquis treatment communicated by the RM tools.
What is the current status of trial NCT02339818?
This trial is currently completed. The enrollment target is 126 participants. The study started on 2015-08. Estimated completion is 2017-02.
Who is sponsoring clinical trial NCT02339818?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.